EXELTIS USA INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELTIS USA INC, and what generic alternatives to EXELTIS USA INC drugs are available?
EXELTIS USA INC has four approved drugs.
There are fourteen US patents protecting EXELTIS USA INC drugs.
There are fifty-five patent family members on EXELTIS USA INC drugs in twenty-nine countries and fifty-eight supplementary protection certificates in fourteen countries.
Summary for EXELTIS USA INC
International Patents: | 55 |
US Patents: | 14 |
Tradenames: | 4 |
Ingredients: | 3 |
NDAs: | 4 |
Drugs and US Patents for EXELTIS USA INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 10,603,281 | ⤷ Sign Up | ⤷ Sign Up | ||||
Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 11,291,633 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | 9,603,860 | ⤷ Sign Up | ⤷ Sign Up | ||||
Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 11,951,213 | ⤷ Sign Up | ⤷ Sign Up | ||||
Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 10,179,140 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EXELTIS USA INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Exeltis Usa Inc | ESTRASORB | estradiol hemihydrate | EMULSION;TOPICAL | 021371-001 | Oct 9, 2003 | 5,629,021 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EXELTIS USA INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20190073598 | ⤷ Sign Up |
Australia | 2011273605 | ⤷ Sign Up |
France | 20C1020 | ⤷ Sign Up |
South Africa | 201209743 | ⤷ Sign Up |
Spain | 2908657 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EXELTIS USA INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3632448 | 122022000040 | Germany | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 7002248.00.00 20210426; FIRST REGISTRATION: DAENEMARK 61678 20191016 |
0136011 | 2000C/027 | Belgium | ⤷ Sign Up | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
2588114 | CA 2020 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016 |
1453521 | 132016000025143 | Italy | ⤷ Sign Up | PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414 |
3632448 | CA 2022 00016 | Denmark | ⤷ Sign Up | PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.